arrow
N

Norikazu Masuda

Graduate School of Medicine
H指数:64
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multicenter development and validation of a serum microRNA–based diagnostic model for breast cancer and its association with tumor burden and biological aggressiveness: an observational case-control study

多中心开发和验证基于血清微RNA的乳腺癌诊断模型及其与肿瘤负荷和生物侵袭性的关联:一项观察性病例对照研究

2026-08-060
OAAI
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD

甲磺酸艾瑞布林与多西他赛或紫杉醇联合曲妥珠单抗和帕妥珠单抗作为HER2阳性局部晚期或转移性乳腺癌的一线治疗的疗效和安全性:JBCRG-M06/EMERALD研究的更新亚组分析

2026-07-080
PRE
Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE

转移性三阴性乳腺癌患者中阿替利珠单抗联合白蛋白结合型紫杉醇的队列观察性研究:JBCRG-C08/ATTRIBUTE

2026-06-260
OA
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer

在JBCRG-M06/EMERALD研究中评估厄洛替尼联合双重HER2阻断在HER2阳性局部晚期或转移性乳腺癌中的生活质量评估

2026-06-100
PRE
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)

随机化、多中心II期研究:贝伐珠单抗和紫杉醇诱导后使用阿替利珠单抗和nab-紫杉醇治疗PD-L1阳性转移性三阴性乳腺癌患者的方案(INDUCE试验[JBCRG-M10])

2026-05-130
PRE
Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group

日本老年HR+/HER2-晚期乳腺癌患者接受帕博西利联合内分泌治疗的实际疗效:P-BRIDGE研究的按年龄分组的亚组分析

2026-02-110
OAAI
Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2− advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

更正: 日本HR /HER2 − 晚期乳腺癌患者一线或二线接受palbociclib联合内分泌治疗的总生存率: 一项多中心观察性研究 (p-bridge研究)

2026-01-270
OAAI
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02

Tucatinib和trastuzumab emtansine用于既往治疗过的HER2阳性局部晚期和转移性乳腺癌患者:随机III期试验HER2CLIMB-02的主要分析

2025-11-170
OAAI
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey

ER阳性、HER2阴性原发性乳腺癌的辅助S-1联合内分泌治疗:POTENT试验后的预后调查

2025-10-240
OA
Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis

日本接受帕博西利+来曲唑一线治疗的ER+/HER2-晚期乳腺癌患者的总生存期及后续治疗模式:最终分析

2025-08-210
OAAI
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)

通过移动应用程序和可穿戴设备收集的HR+/HER2−晚期乳腺癌患者接受帕博西利比联合内分泌治疗或单纯内分泌治疗后的健康相关生活质量与身体活动:6个月纵向研究(JBCRG-26)

2025-07-180
OA
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer

更正:来自日本的真实世界证据显示,在接受CDK4/6抑制剂联合内分泌疗法作为一线或二线治疗激素受体阳性、HER2阴性晚期或转移性乳腺癌患者的生存结局及治疗顺序方面的数据。

2025-06-230
OAAI
Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational study

乳腺癌患者中,伴有1至3个阳性微转移或巨转移的哨兵淋巴结的腋窝手术:一项观察性研究

2025-05-250
OAAI
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

来自日本的真实世界证据,关于接受CDK4/6抑制剂联合内分泌治疗作为激素受体阳性、HER2阴性晚期或转移性乳腺癌的一线或二线治疗患者的生存结局及治疗顺序。

2025-05-200
OA